SWA
MRNS

SOA Wealth Advisors’s Marinus Pharmaceuticals, Inc MRNS Stock Holding History

SOA Wealth Advisors’s Portfolio MRNS Stock Details MRNS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-40
Closed -$435 – 929
2023
Q4 		$435 Buy
+40
New +$300 ﹤0.01% 807

Other funds holding MRNS

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return

SOA Wealth Advisors's MRNS Position: Q1 2024 in Review

SOA Wealth Advisors sold out of Marinus Pharmaceuticals, Inc (MRNS) in Q1 2024, closing a stake of 40 shares — an estimated $435 sold.

SOA Wealth Advisors first reported a position in MRNS in Q4 2023 and held it in 1 quarter. The position peaked at $435 in Q4 2023. 112 funds tracked by Wall St. Rank hold MRNS as of Q1 2024.

  • SOA Wealth Advisors reported no remaining Marinus Pharmaceuticals, Inc position as of Q1 2024 after selling out during the quarter.
  • SOA Wealth Advisors sold 40 Marinus Pharmaceuticals, Inc shares in Q1 2024, an estimated $435.
  • SOA Wealth Advisors first reported a position in Marinus Pharmaceuticals, Inc in Q4 2023 and held it in 1 quarter.
  • SOA Wealth Advisors's Marinus Pharmaceuticals, Inc position peaked at $435 in Q4 2023.
  • 112 funds tracked by Wall St. Rank held Marinus Pharmaceuticals, Inc as of Q1 2024.

Based on SOA Wealth Advisors's 13F filing for Q1 2024, filed 10 Apr 2024.